Cannell & Co’s Teva Pharmaceuticals TEVA Stock Holding History

Cannell & Co’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-31,095	Closed	-$300K	–	291
2020 Q4	$300K	Buy	+31,095	New	+$298K	0.01%	241
2017 Q3	–	Sell	-6,384	Closed	-$212K	–	245
2017 Q2	$212K	Hold	6,384	–	–	0.01%	233
2017 Q1	$205K	Sell	6,384 -1,000	-14%	-$34.1K	0.01%	240
2016 Q4	$268K	Hold	7,384	–	–	0.01%	227
2016 Q3	$340K	Hold	7,384	–	–	0.01%	223
2016 Q2	$371K	Hold	7,384	–	–	0.01%	219
2016 Q1	$395K	Sell	7,384 -400	-5%	-$23.5K	0.01%	216
2015 Q4	$511K	Sell	7,784 -500	-6%	-$30.9K	0.02%	202
2015 Q3	$468K	Hold	8,284	–	–	0.02%	208
2015 Q2	$490K	Hold	8,284	–	–	0.01%	201
2015 Q1	$516K	Hold	8,284	–	–	0.01%	195
2014 Q4	$476K	Hold	8,284	–	–	0.01%	201
2014 Q3	$445K	Hold	8,284	–	–	0.01%	210
2014 Q2	$434K	Sell	8,284 -700	-8%	-$35.8K	0.01%	210
2014 Q1	$475K	Buy	+8,984	New	+$415K	0.02%	215

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Cannell & Co's TEVA Position: Q1 2021 in Review

Cannell & Co sold out of Teva Pharmaceuticals (TEVA) in Q1 2021, closing a stake of 31,095 shares — an estimated $300K sold.

Cannell & Co first reported a position in TEVA in Q1 2014 and held it in 15 quarters. The position peaked at $516K in Q1 2015. 451 funds tracked by Wall St. Rank hold TEVA as of Q1 2021.

Cannell & Co reported no remaining Teva Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Cannell & Co sold 31,095 Teva Pharmaceuticals shares in Q1 2021, an estimated $300K.
Cannell & Co first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 15 quarters.
Cannell & Co's Teva Pharmaceuticals position peaked at $516K in Q1 2015.
451 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2021.

Based on Cannell & Co's 13F filing for Q1 2021, filed 7 May 2021.